The Trump administration is seeking to restrict American investment in Chinese biotechnology companies, potentially complicating financial ties at a time when US drugmakers are increasingly turning to China for new medicines.

The White House is reviewing a proposal to broaden access to peptides that includes more patient protections than initially expected, according to people familiar with the matter.

The pharmaceutical industry is focused on getting AI to make us healthier.

Hims & Hers Health Inc. reported a first-quarter loss and sales that missed Wall Street estimates as it faces higher costs associated with its strategic pivot to branded weight-loss medications.

President Donald Trump pulled the nomination of wellness entrepreneur Casey Means to be US surgeon general and named Nicole Saphier, a radiologist, to replace her.

Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result as fewer-than-expected infections in the pivotal study made its potency hard to evaluate.

Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.’s platform, according to a person familiar with the matter, ending a highly public feud between the two companies that spiraled into a legal battle last month.

The head of the US Food and Drug Administration’s division of vaccines and gene therapies is leaving the agency after a tumultuous tenure, sending biotech shares higher in late trading on Friday.

US Food and Drug Administration Commissioner Marty Makary defended against accusations his top deputy is unfairly rejecting promising drugs, in a combative television interview with CNBC on Thursday that added to pressure the agency is facing over how it’s run.

Eli Lilly & Co agreed to buy closely held US biotech Orna Therapeutics Inc. for up $2.4 billion in cash, its second deal in two days as the company expands its pipeline beyond its well-known blockbuster obesity drug Zepbound.

President Donald Trump launched a new website to help Americans directly buy select medicines at a discount, seeking to counter cost-of-living concerns that pose a threat to his party in November’s congressional elections.

Within the span of 19 hours, weight loss drugmakers Novo Nordisk A/S and Eli Lilly & Co. offered wildly divergent views on where business is headed. After Novo shocked the market by warning sales could decline by as much as 13% this year, Lilly followed with a surprise to the upside, forecasting an as much as 27% rise.

Nvidia Corp. plans to invest $1 billion over five years in a new laboratory with Eli Lilly & Co., aiming to speed up the use of artificial intelligence in the pharmaceutical industry.